<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Surgery and Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Surgery and Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Хирургия и онкология</trans-title></trans-title-group></journal-title-group><issn publication-format="electronic">2949-5857</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">76</article-id><article-id pub-id-type="doi">10.17650/2220-3478-2014-0-3-23-28</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">COMBINATION NEOADJUVANT THERMOCHEMICAL THERAPY IN PATIENTS WITH RECTAL CANCER</article-title><trans-title-group xml:lang="ru"><trans-title>КОМПЛЕКСНОЕ ЛЕЧЕНИЕ БОЛЬНЫХ РАКОМ ПРЯМОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ НЕОАДЪЮВАНТНОЙ ТЕРМОХИМИОЛУЧЕВОЙ ТЕРАПИИ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Barsukov</surname><given-names>Yu. A.</given-names></name><name xml:lang="ru"><surname>Барсуков</surname><given-names>Ю. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ss@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kuzmichev</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Кузьмичев</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ss@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tkachev</surname><given-names>S. I.</given-names></name><name xml:lang="ru"><surname>Ткачев</surname><given-names>С. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ss@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Aliev</surname><given-names>V. A.</given-names></name><name xml:lang="ru"><surname>Алиев</surname><given-names>В. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ss@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tamrazov</surname><given-names>R. I.</given-names></name><name xml:lang="ru"><surname>Малихов</surname><given-names>А. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ss@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Malikhov</surname><given-names>A. G.</given-names></name><name xml:lang="ru"><surname>Мамедли</surname><given-names>З. З.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ss@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mamedli</surname><given-names>Z. Z.</given-names></name><name xml:lang="ru"><surname>Татаев</surname><given-names>И. Ш.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ss@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tataev</surname><given-names>I. Sh.</given-names></name><name xml:lang="ru"><surname>Власов</surname><given-names>О. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ss@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vlasov</surname><given-names>O. A.</given-names></name><name xml:lang="ru"><surname>Гордеев</surname><given-names>С. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ss@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gordeev</surname><given-names>S. S.</given-names></name><name xml:lang="ru"><surname>Тамразов</surname><given-names>Р. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ss@oncoproct.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow</institution></aff><aff><institution xml:lang="ru">ФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2014-09-26" publication-format="electronic"><day>26</day><month>09</month><year>2014</year></pub-date><volume>3</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>23</fpage><lpage>28</lpage><history><date date-type="received" iso-8601-date="2015-02-28"><day>28</day><month>02</month><year>2015</year></date><date date-type="accepted" iso-8601-date="2015-02-28"><day>28</day><month>02</month><year>2015</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Barsukov Y.A., Kuzmichev D.V., Tkachev S.I., Aliev V.A., Tamrazov R.I., Malikhov A.G., Mamedli Z.Z., Tataev I.S., Vlasov O.A., Gordeev S.S.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, Барсуков Ю.А., Кузьмичев Д.В., Ткачев С.И., Алиев В.А., Малихов А.Г., Мамедли З.З., Татаев И.Ш., Власов О.А., Гордеев С.С., Тамразов Р.И.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Barsukov Y.A., Kuzmichev D.V., Tkachev S.I., Aliev V.A., Tamrazov R.I., Malikhov A.G., Mamedli Z.Z., Tataev I.S., Vlasov O.A., Gordeev S.S.</copyright-holder><copyright-holder xml:lang="ru">Барсуков Ю.А., Кузьмичев Д.В., Ткачев С.И., Алиев В.А., Малихов А.Г., Мамедли З.З., Татаев И.Ш., Власов О.А., Гордеев С.С., Тамразов Р.И.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://onco-surgery.info/jour/article/view/76">https://onco-surgery.info/jour/article/view/76</self-uri><abstract xml:lang="en"><p>A new combined treatment scheme with short-course chemoradiotherapy and 2 selective radiosensitizers (metronidazole in a polymeric composition and local hyperthermia) is investigated in this article.</p><p><bold>Material and methods. </bold>77 T1–3N0–2M0 rectal cancer patients treatment data was analyzed. All patients received 5 Ч 5 Gy radiotherapy with capecitabine 1300 mg/m2 days 1–5 per os and radiosensitization with local hyperthermia and metronidazole.</p><p><bold>Results. </bold>Investigated treatment scheme has acceptable toxicity and leads to high local control rate (none of the patients experienced local recurrence). 7 (9.1 %) patients developed distant metastases. 59 (76.6 %) patients had sphincter-sparing surgery. Median followup was 65.6 months. 5-year survival rate was 81.7 %.</p><p><bold>Conclusion. </bold>Developed treatment scheme is safe and leads to high local control rate.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>rectal cancer</kwd><kwd>combination therapy</kwd><kwd>local ultrahigh-frequency hyperthermia</kwd><kwd>metronidazole</kwd><kwd>systemic chemotherapy</kwd><kwd>sphinctersparing surgery</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак прямой кишки</kwd><kwd>комплексная терапия</kwd><kwd>локальная СВЧ-гипертермия</kwd><kwd>метронидазол</kwd><kwd>системная химиотерапия</kwd><kwd>сфинктерохраняющие операции</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Кныш В.И. Рак прямой и ободочной кишки. М., 2003. 250 с.</mixed-citation><mixed-citation xml:lang="ru">Кныш В.И. Рак прямой и ободочной кишки. М., 2003. 250 с.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Van Gijn W., Marijnen C. A., Nagtegaal I.D. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011 Jun;12(6):575–82.</mixed-citation><mixed-citation xml:lang="ru">Van Gijn W., Marijnen C. A., Nagtegaal I.D. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011 Jun;12(6):575–82.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. De Caluwe L., Van Nieuwenhove Y., Ceelen W.P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2013;2:CD006041.</mixed-citation><mixed-citation xml:lang="ru">De Caluwe L., Van Nieuwenhove Y., Ceelen W.P. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2013;2:CD006041.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Tepper J.E., Wang A.Z. Improving local control in rectal cancer: Radiation sensitizers or radiation dose? J Clin Oncol 2010;28:1623–4.</mixed-citation><mixed-citation xml:lang="ru">Tepper J.E., Wang A.Z. Improving local control in rectal cancer: Radiation sensitizers or radiation dose? J Clin Oncol 2010;28:1623–4.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Зыбина М.А. Комбинированное лечение с интенсивным предоперационным облучением и расширенные оперативные вмешательства при раке прямой кишки. Дис. … д-ра мед. наук. М., 1975. 457 с.</mixed-citation><mixed-citation xml:lang="ru">Зыбина М.А. Комбинированное лечение с интенсивным предоперационным облучением и расширенные оперативные вмешательства при раке прямой кишки. Дис. … д-ра мед. наук. М., 1975. 457 с.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Мельников Р.А., Павлюк В.Д., Симбирцева Л.П., Столяров В.И. Комбинированное лечение рака желудочно-кишечного тракта. Кишинев: Штиинца, 1983. 216 с.</mixed-citation><mixed-citation xml:lang="ru">Мельников Р.А., Павлюк В.Д., Симбирцева Л.П., Столяров В.И. Комбинированное лечение рака желудочно-кишечного тракта. Кишинев: Штиинца, 1983. 216 с.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Дедков И.П., Черниченко В.А. Комбинированное лечение злокачественных опухолей. Киев: Здоров’я, 1975. 183 с.</mixed-citation><mixed-citation xml:lang="ru">Дедков И.П., Черниченко В.А. Комбинированное лечение злокачественных опухолей. Киев: Здоров’я, 1975. 183 с.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Кныш В.И., Бондарь Г.В., Алиев Б.М., Барсуков Ю.А. Комбинированное и комплексное лечение рака прямой кишки. М.: Медицина, 1990. 160 с.</mixed-citation><mixed-citation xml:lang="ru">Кныш В.И., Бондарь Г.В., Алиев Б.М., Барсуков Ю.А. Комбинированное и комплексное лечение рака прямой кишки. М.: Медицина, 1990. 160 с.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Бердов Б.А., Невольских А.А., Ерыгин Д.В., Титова Л.Н. Лечение местно-распространенного рака прямой кишки. Вопросы онкологии 2007;53(5):578–83.</mixed-citation><mixed-citation xml:lang="ru">Бердов Б.А., Невольских А.А., Ерыгин Д.В., Титова Л.Н. Лечение местно-распространенного рака прямой кишки. Вопросы онкологии 2007;53(5):578–83.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Ерыгин Д.В., Бердов Б.А., Невольских A.A. и др. Местно-распространенный рак пря- мой кишки – пути улучшения результатов лечения. В сб.: Материалы I съезда колопроктологов СНГ. Ташкент, 2009. С. 149–150.</mixed-citation><mixed-citation xml:lang="ru">Ерыгин Д.В., Бердов Б.А., Невольских A.A. и др. Местно-распространенный рак пря- мой кишки – пути улучшения результатов лечения. В сб.: Материалы I съезда колопроктологов СНГ. Ташкент, 2009. С. 149–150.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Направленная доставка лекарственных препаратов при лечении онкологических больных. Под. ред. А.В. Бойко, Л.И. Корытовой, Н.Д. Олтаржевской. М., 2013. 194 с.</mixed-citation><mixed-citation xml:lang="ru">Направленная доставка лекарственных препаратов при лечении онкологических больных. Под. ред. А.В. Бойко, Л.И. Корытовой, Н.Д. Олтаржевской. М., 2013. 194 с.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Дарьялова С.Л., Поляков П.Ю., Киселева Е.С. и др. Метронидазол при лучевом лечении злокачественных новообразований. Медицинская радиология 1986;7:6–13.</mixed-citation><mixed-citation xml:lang="ru">Дарьялова С.Л., Поляков П.Ю., Киселева Е.С. и др. Метронидазол при лучевом лечении злокачественных новообразований. Медицинская радиология 1986;7:6–13.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Пелевина И.И., Воронина С.С., Каракулов Р.К. Метронидазол, основные экспериментальные результаты, перспективы для клиники. Медицинская радиология 1984;2:10–20.</mixed-citation><mixed-citation xml:lang="ru">Пелевина И.И., Воронина С.С., Каракулов Р.К. Метронидазол, основные экспериментальные результаты, перспективы для клиники. Медицинская радиология 1984;2:10–20.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Ярмоненко С.П., Вайнсон А.А. Радиобиология человека и животных. Уч. пособ. М.: Высшая школа, 2004. 552 с.</mixed-citation><mixed-citation xml:lang="ru">Ярмоненко С.П., Вайнсон А.А. Радиобиология человека и животных. Уч. пособ. М.: Высшая школа, 2004. 552 с.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Барсуков Ю.А., Ткачев С.И., Кныш В.И. и др. Лечение рака прямой кишки с использованием нескольких радиомодификаторов при предоперационной лучевой терапии. Медицинская радиология и радиационная безопасность 2008;53(2):25–30.</mixed-citation><mixed-citation xml:lang="ru">Барсуков Ю.А., Ткачев С.И., Кныш В.И. и др. Лечение рака прямой кишки с использованием нескольких радиомодификаторов при предоперационной лучевой терапии. Медицинская радиология и радиационная безопасность 2008;53(2):25–30.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Барсуков Ю.А., Олтаржевская Н.Д, Ткачев С.И. и др. Способ лечения рака прямой кишки. Патент на изобретение № 2234318. Зарегистрирован в Государственном реестре изобретений РФ 20.08.2004.</mixed-citation><mixed-citation xml:lang="ru">Барсуков Ю.А., Олтаржевская Н.Д, Ткачев С.И. и др. Способ лечения рака прямой кишки. Патент на изобретение № 2234318. Зарегистрирован в Государственном реестре изобретений РФ 20.08.2004.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Барсуков Ю.А. Комбинированное и комплексное лечение больных раком прямой кишки. Дис. … д-ра мед. наук., М., 1991. 438 с.</mixed-citation><mixed-citation xml:lang="ru">Барсуков Ю.А. Комбинированное и комплексное лечение больных раком прямой кишки. Дис. … д-ра мед. наук., М., 1991. 438 с.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Мардынский Ю.С., Курпешев O.K., Ткачев С.И. Гипертермия как универсальный радиосенсибилизатор. Тез. док. V Российской онкологической конференции. Москва, 27–29 ноября 2001 г. С. 23–25.</mixed-citation><mixed-citation xml:lang="ru">Мардынский Ю.С., Курпешев O.K., Ткачев С.И. Гипертермия как универсальный радиосенсибилизатор. Тез. док. V Российской онкологической конференции. Москва, 27–29 ноября 2001 г. С. 23–25.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Laszlo A., Fleischer I. Heat-induced perturbations of DNA damage signaling pathways are modulated by molecular chaperones. Cancer Res 2009 Mar 1;69(5): 2042–9.</mixed-citation><mixed-citation xml:lang="ru">Laszlo A., Fleischer I. Heat-induced perturbations of DNA damage signaling pathways are modulated by molecular chaperones. Cancer Res 2009 Mar 1;69(5): 2042–9.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Song C.W, Park H., Griffin R.J. Improvement of tumor oxygenation by mild hyperthermia. Radiat Res 2001;155:515–28.</mixed-citation><mixed-citation xml:lang="ru">Song C.W, Park H., Griffin R.J. Improvement of tumor oxygenation by mild hyperthermia. Radiat Res 2001;155:515–28.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Song C.W., Shakil A., Osborn J.L., Iwata K. Tumour oxygenation is increased by hyperthermia at mild temperatures. 1996. Int J Hyperthermia 2009 Mar;25(2):91–5.</mixed-citation><mixed-citation xml:lang="ru">Song C.W., Shakil A., Osborn J.L., Iwata K. Tumour oxygenation is increased by hyperthermia at mild temperatures. 1996. Int J Hyperthermia 2009 Mar;25(2):91–5.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Hahn G.M., Shiu E.C. Effect of pH and elevated temperatures on the cytotoxicity of some chemotherapeutic agents on Chinese hamster cells in vitro. Cancer Res 1983 Dec;43(12 Pt 1):5789–91.</mixed-citation><mixed-citation xml:lang="ru">Hahn G.M., Shiu E.C. Effect of pH and elevated temperatures on the cytotoxicity of some chemotherapeutic agents on Chinese hamster cells in vitro. Cancer Res 1983 Dec;43(12 Pt 1):5789–91.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Miller R.C., Richards M., Baird C. et al. Interaction of hyperthermia and chemotherapy agents; cell lethality and oncogenic potential. Int J Hyperthermia 1994;10(1):89–99.</mixed-citation><mixed-citation xml:lang="ru">Miller R.C., Richards M., Baird C. et al. Interaction of hyperthermia and chemotherapy agents; cell lethality and oncogenic potential. Int J Hyperthermia 1994;10(1):89–99.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. Takemoto M., Kuroda M., Urano M. et al. The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumours. Int J Hyperthermia 2003;19(2):193–203.</mixed-citation><mixed-citation xml:lang="ru">Takemoto M., Kuroda M., Urano M. et al. The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumours. Int J Hyperthermia 2003;19(2):193–203.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. Дудниченко А.С., Бутенко К.А., Малышенко Ю.И., Фатеев А.С. СВЧ-гипертермия в комбинированном лечении местно-распространенных форм злокачественных новообразований. Тез. II съезда онкологов стран СНГ, Киев, 2000. № 369.</mixed-citation><mixed-citation xml:lang="ru">Дудниченко А.С., Бутенко К.А., Малышенко Ю.И., Фатеев А.С. СВЧ-гипертермия в комбинированном лечении местно-распространенных форм злокачественных новообразований. Тез. II съезда онкологов стран СНГ, Киев, 2000. № 369.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">26. Конопляников А.Г., Штейн Л.В. Использование гипертермии для подавления репаративных процессов в опухолевых клетках и для повышения эффективности лучевой терапии. Медицинская радиология 1977;22(2):23–7.</mixed-citation><mixed-citation xml:lang="ru">Конопляников А.Г., Штейн Л.В. Использование гипертермии для подавления репаративных процессов в опухолевых клетках и для повышения эффективности лучевой терапии. Медицинская радиология 1977;22(2):23–7.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">27. Byfield J.E. Useful interactions between 5-fluorouracil and radiation in man: 5-fluorouracil as a radiosensitizer. In: Antitumor Drug-radiation Interactions. Hill B.T. and Bellamy A.S. (eds). Boca Raton, FL: CRC Press, 1990. P. 87–105.</mixed-citation><mixed-citation xml:lang="ru">Byfield J.E. Useful interactions between 5-fluorouracil and radiation in man: 5-fluorouracil as a radiosensitizer. In: Antitumor Drug-radiation Interactions. Hill B.T. and Bellamy A.S. (eds). Boca Raton, FL: CRC Press, 1990. P. 87–105.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">28. Lawrence T.S., Burke R., Davis M.A. Lack of effect of TP53 status on fluorodeoxyuridinemediated radiosensitization. Radiat Res 2000;154(2):140–144.</mixed-citation><mixed-citation xml:lang="ru">Lawrence T.S., Burke R., Davis M.A. Lack of effect of TP53 status on fluorodeoxyuridinemediated radiosensitization. Radiat Res 2000;154(2):140–144.</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">29. Davis M.A., Tang H.Y., Maybaum J., Lawrence T.S. Dependence of fluorodeoxyuridine-mediated radiosensitization on S phase progression. Int J Radiat Biol 1995;67(5):509–17.</mixed-citation><mixed-citation xml:lang="ru">Davis M.A., Tang H.Y., Maybaum J., Lawrence T.S. Dependence of fluorodeoxyuridine-mediated radiosensitization on S phase progression. Int J Radiat Biol 1995;67(5):509–17.</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">30. Hwang H.S., Davis T.W., Houghton J.A., Kinsella T.J. Radiosensitivity of thymidylate synthase-deficient human tumor cells is affected by progression through the G1 restriction point into S-phase: Implications for fluoropyrimidine radiosensitization. Cancer Res 2000;60(1):92–100.</mixed-citation><mixed-citation xml:lang="ru">Hwang H.S., Davis T.W., Houghton J.A., Kinsella T.J. Radiosensitivity of thymidylate synthase-deficient human tumor cells is affected by progression through the G1 restriction point into S-phase: Implications for fluoropyrimidine radiosensitization. Cancer Res 2000;60(1):92–100.</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">31. Lawrence T.S., Davis M.A., Loney T.L. Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation. Cancer Res 1996;56(14):3203–6.</mixed-citation><mixed-citation xml:lang="ru">Lawrence T.S., Davis M.A., Loney T.L. Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation. Cancer Res 1996;56(14):3203–6.</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">32. Ojima E., Inoue Y., Watanabe H. et al. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines. Oncol Rep 2006;16(5):1085–91.</mixed-citation><mixed-citation xml:lang="ru">Ojima E., Inoue Y., Watanabe H. et al. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines. Oncol Rep 2006;16(5):1085–91.</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">33. Yoshikawa R., Kusunoki M., Yanagi H. et al. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 2001;61(3):1029–37.</mixed-citation><mixed-citation xml:lang="ru">Yoshikawa R., Kusunoki M., Yanagi H. et al. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 2001;61(3):1029–37.</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">34. Sawada N., Ishikawa T., Sekiguchi F. et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999 Oct;5(10):2948–53.</mixed-citation><mixed-citation xml:lang="ru">Sawada N., Ishikawa T., Sekiguchi F. et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999 Oct;5(10):2948–53.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
